Skip to main content

Market Overview

Otonomy's OTO-825 Gene Therapy Can Restore Meaningful Hearing Function, Animal Study Shows

Share:
Otonomy's OTO-825 Gene Therapy Can Restore Meaningful Hearing Function, Animal Study Shows
  • Otonomy Inc (NASDAQ: OTIC) may have hit a snag with the development of its lead ear disorder candidate Otividex. Still, the company is trumpeting an early win for a gene therapy designed to treat congenital hearing loss.
  • The drug candidate, dubbed OTO-825, reduced hearing loss and repaired structural damage in the inner ear in two mouse models of genetically driven hearing deficiency. Otonomy and its partner Applied Genetic Technologies Corporation (NASDAQ: AGTC) reported the data at the American Society of Gene & Cell Therapy annual meeting.
  • The OTO-825 news came on the heels of the phase 3 failure of Otonomy’s former lead candidate Otividex to treat the inner ear condition Ménière’s disease.
  • Based on the encouraging results, the companies are preparing an FDA application to start a first-in-human clinical trial.
  • Otonomy tested OTO-825 in two different mouse models with partially crippled GJB2 to mimic severe and intermediate hearing loss in humans.
  • According to the presentation, one injection administered into the inner ears of the mice improved the animals’ hearing function and the organ’s structure.
  • There are three rows of outer hair cells in a normal mouse and a single row of inner hair cells in the cochlea. These are damaged or missing in the genetically modified mice with dysfunctional GJB2. But OTO-825 restored those structures, a showing that was consistent with the hearing function improvement.
  • Price Action: OTIC shares are up 2.14% at $2.15, and AGTC shares are up 5.7% at $3.88 during the market session on the last check Friday.
 

Related Articles (AGTC + OTIC)

View Comments and Join the Discussion!

Posted-In: Briefs gene therapyBiotech News Penny Stocks Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com